Metabolic Imaging as a Biomarker of Early Radiation Response in Tumors.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26232369.
- Also identified by DOI 10.1158/1078-0432.CCR-15-1214 and PMC identifier 4644683.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
(13)C-pyruvate hyperpolarized magnetic resonance imaging (HP-MRI) is emerging as a viable quantitative biomarker for solid tumor response and normal tissue toxicity after radiotherapy. This technology effectively predicts response related to metabolic agents or alterations in the tumor microenvironment, but challenges remain to be addressed to ensure successful translational implementation. See related article by Saito et al., p. 5073.
Medical subject headings
- Magnetic Resonance Imaging
- Neoplasms